The global market for Positron Emission Tomography (PET) devices is set to surge — projected to climb from USD 3.96 billion in 2024 to USD 8.50 billion by 2035 (CAGR: 7.19%). This growth reflects expanding need for advanced, reliable diagnostics as chronic disease, cancer cases, and geriatric populations rise worldwide. Demand is also fueled by rapid improvements in imaging technologies — such as PET/CT, PET/MRI hybrids and digital PET systems — making diagnostic procedures faster, more accurate, and widely accessible.

PET imaging remains indispensable in oncology, cardiology, neurology and infection detection — thanks to its ability to capture metabolic activity, often revealing disease long before structural changes appear. As hospitals, diagnostic centers and research institutes upgrade their imaging infrastructure, the PET devices market is primed for robust expansion across developed and emerging regions alike.

 (FAQ)

Q1: What makes PET scans more effective than conventional imaging (like MRI or CT)?
A: Unlike CT or MRI, which show anatomical structures, PET reveals metabolic and functional activity — highlighting disease processes at the cellular level. That means cancers, neurological disorders or cardiac dysfunction can often be detected earlier, improving diagnosis, staging and treatment planning.

Q2: Which applications drive the highest demand for PET devices globally?
A: The biggest demand arises from oncology — for tumor detection, staging, therapy monitoring and recurrence checks. Cardiology (heart conditions) and neurology (brain disorders such as dementia) follow closely as growth areas, especially as awareness and availability increase worldwide.